332 related articles for article (PubMed ID: 35199608)
1. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
Khiali S; Khani E; B Rouy S; Entezari-Maleki T
Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
Bai Y; Shen M; Zhang L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
5. Molnupiravir in COVID-19: A systematic review of literature.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
[TBL] [Abstract][Full Text] [Related]
6. Molnupiravir: A new candidate for COVID-19 treatment.
Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
[TBL] [Abstract][Full Text] [Related]
7. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
[TBL] [Abstract][Full Text] [Related]
11. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
[TBL] [Abstract][Full Text] [Related]
12. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Waters MD; Warren S; Hughes C; Lewis P; Zhang F
Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
[TBL] [Abstract][Full Text] [Related]
13. RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H
Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743
[TBL] [Abstract][Full Text] [Related]
14. What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
Kayali F; Leung MST; Wong W; Morgan KP; Harky A
Expert Opin Pharmacother; 2022 Jun; 23(8):865-868. PubMed ID: 35341442
[No Abstract] [Full Text] [Related]
15. First-generation oral antivirals against SARS-CoV-2.
Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
[TBL] [Abstract][Full Text] [Related]
16. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
[TBL] [Abstract][Full Text] [Related]
18. A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy.
Sakander N; Ahmed A; Bhardwaj M; Kumari D; Nandi U; Mukherjee D
Bioorg Chem; 2024 Jun; 147():107379. PubMed ID: 38643567
[TBL] [Abstract][Full Text] [Related]
19. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir.
Al-Taie A; Denkdemir FR; Sharief Z; Buyuk AS; Şardaş S
OMICS; 2022 Jun; 26(6):324-328. PubMed ID: 35580151
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
